Fast-track analysis for first-line treatment

Frequently, a very rapid decision for a first-line treatment is necessary after the diagnosis of lung cancer. To bring our philosophy of a comprehensive, best possible molecular diagnostics into line with the need for rapid decision-making for a potential molecular therapy, since early 2015, and in addition to the comprehensive diagnostics by multiplex PCR or hybrid capture sequencing, we carry out a so-called Fast-Track Analysis for individual parameters which are very important for the first-line treatment (EGFR, ALK, KRAS, possibly also ROS1). Requesting physician are provided with these parameters within 4 working days in advance.
Netzwerk Genomische Medizin (NGM) Lungenkrebs

Last update: 07. March 2016 , 12:04

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.